CJC-1295 + DAC 5mg Research Peptide

For Research Purposes Only. Not approved for human consumption.

CJC-1295 + DAC Research Peptide 5mg

CJC-1295 with DAC is engineered for extended half-life (~6-8 days) through covalent albumin binding via its maleimidoproprionic acid group. This creates a sustained depot effect maintaining GHRH receptor stimulation over an extended period — ideal for research protocols requiring chronic, sustained GH elevation with less frequent administration than the No DAC version.

Research Applications

• Chronic GH elevation research models
• Long-term hypothalamic-pituitary studies
• IGF-1 sustained elevation investigations
• Comparison studies vs. pulsatile GHRH analogs
• Extended GH exposure body composition research

Quality Specifications

• Purity: ≥98% (HPLC verified)
• Compound: CJC-1295 (DAC)
• Molecular Weight: ~3647 Da
• Form: Lyophilized powder
• Storage: -20°C, protect from light
• COA: Batch-specific, ISO-accredited laboratory

Frequently Asked Questions

Q: How does albumin binding extend half-life?
A: The DAC maleimide group reacts with a free cysteine on serum albumin, tethering the peptide to the most abundant plasma protein and drastically slowing clearance rate.

Q: Can CJC-1295 DAC still be combined with GHRPs?
A: Yes. DAC provides sustained GHRH receptor background; GHRPs provide pulsatile ghrelin receptor stimulation. Many researchers combine both for comprehensive GH axis studies.

Q: What is the research advantage of long-acting GHRH?
A: Allows longitudinal studies of downstream GH/IGF-1 effects without frequent dosing — more practical for extended study designs.

Related Research: CJC-1295 No DAC | Ipamorelin | Sermorelin Research Peptide

For laboratory research use only. Not for human consumption. Not evaluated by the FDA.